DEXACORT
LOE ApproachingNDANASALAEROSOL
Approved
Dec 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXACORT is a nasal aerosol small-molecule corticosteroid approved in 1965 for intranasal use. The exact indications are not specified in available data, but nasal corticosteroids are typically used to treat allergic rhinitis, nasal inflammation, and related upper airway conditions. The drug works via glucocorticoid receptor binding to reduce inflammatory cytokine production and immune cell infiltration.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30) suggests a mature brand with declining strategic importance and smaller team footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DEXACORT offers limited career growth as the product approaches loss of exclusivity and faces commoditization. Roles focus on margin protection, managed care negotiation, and portfolio transition rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on DEXACORT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.